Ocular Surface Changes in Patients With Cystic Fibrosis

NCT00345280 — Unknown, 26 participants, University of Bialystok

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Chosen Parameters of the Immune Response in the Origin of Ocular Changes in Patients With Cystic Fibrosis

Registry	NCT00345280
Status	Unknown
Study type	Observational
Enrollment	26 (Estimated)
Sponsor	University of Bialystok (Other gov)
Conditions	Eye Manifestations
Interventions	impression cytology, obtain the tear fluid (Procedure)
Dates	start 2006-08-01, completion 2008-09-01 (estimated), first posted 2006-06-28, last updated 2008-06-17
Locations	1 site in Poland

-Summary

Cystic fibrosis(CF) is an inherited disease affecting children, adolescents and young adults with dysfunction of secretory glands.It is caused by mutations in the protein-coding gene which function as the cystic fibrosis transmembrane regulator (CFTR), responsible for the secretion of chloride ions in epithelial cells, adenocytes, sweat gland cells, pancreatic ducts,alimentary and respiratory tracts and eye. Assessment of the relationship between the inflammatory processes and apoptosis in the eye in the course of cystic fibrosis will allow determination of immunological exponents which may facilitate diagnosis.

Expand all sections · Collapse all

+Detailed description

The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

+Arms and interventions

impression cytology, obtain the tear fluid (Procedure), also known as Becton Dickinson: Vitamin A

+Eligibility

Sex: All, ages: 3 Years to 25 Years, accepts healthy volunteers

Inclusion Criteria:

* male and female patients aged 3-25 with clinically definite diagnosis of cystic fibrosis
* all patients must give written consent for participation in the study at screening

Exclusion Criteria:

* patients with a history of chronic disease of the immune system
* patients with the history of systemic diseases
* patients with the history chronic ocular diseases
* patients who have been treated with corticosteroids in the past 3 months prior to the screening visit

+Locations (1)

Facility	City	Country	Status
Medical University	Bialystok	Poland	Recruiting

+Investigators

Malgorzata Mrugacz, MD, PhD, Principal investigator, Department of Pediatric Ophthalmology Medical University of Bialystok, Poland